The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530

Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 13, 1011, 10.1016/S1470-2045(12)70344-3

Kim D AM, Yang P, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) [abstract]. Paper presented at the European Society for Medical Oncology 2012 Congress. September 28–October 2, 2012; Vienna, Austria:2252.

Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440

Shaw, 2015, Crizotinib in ROS1-rearranged non-small-cell lung cancer, N Engl J Med, 372, 683, 10.1056/NEJMc1415359

Waqar, 2015, MET Mutation associated with responsiveness to crizotinib, J Thorac Oncol, 10, e29, 10.1097/JTO.0000000000000478

Camidge, 2014, Efficacy and safety of crizotinib inpatients with advanced c-MET-amplified non-small cell lung cancer (NSCLC), Am J Clin Oncol, 32, 8001, 10.1200/jco.2014.32.15_suppl.8001

Garber, 2014, MET inhibitors start on road to recovery, Nat Rev Drug Discov, 13, 563, 10.1038/nrd4406

Ma, 2015, MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker, Cancer Discov, 5, 802, 10.1158/2159-8290.CD-15-0769

Ma, 2005, Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer, Cancer Res, 65, 1479, 10.1158/0008-5472.CAN-04-2650

Kong-Beltran, 2006, Somatic mutations lead to an oncogenic deletion of met in lung cancer, Cancer Res, 66, 283, 10.1158/0008-5472.CAN-05-2749

Lee, 2014, Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody, Oncogene, 33, 34, 10.1038/onc.2012.551

Lee, 2006, An alternatively spliced form of Met receptor is tumorigenic, Exp Mol Med, 38, 565, 10.1038/emm.2006.66

Frampton, 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors, Cancer Discov, 5, 850, 10.1158/2159-8290.CD-15-0285

Paik, 2015, Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping, Cancer Discov, 5, 842, 10.1158/2159-8290.CD-14-1467

Awad, 2016, MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, J Clin Oncol, 34, 721, 10.1200/JCO.2015.63.4600

Tsuda, 2001, Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression, Cancer, 92, 2965, 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO;2-A

Bergethon, 2012, ROS1 rearrangements define a unique molecular class of lung cancers, J Clin Oncol, 30, 863, 10.1200/JCO.2011.35.6345

Rodig, 2009, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin Cancer Res, 15, 5216, 10.1158/1078-0432.CCR-09-0802

Awad, 2016, MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, J Clin Oncol, 34, 721, 10.1200/JCO.2015.63.4600

Mendenhall, 2015, MET-mutated NSCLC with major response to crizotinib, J Thorac Oncol, 10, e33, 10.1097/JTO.0000000000000491

Jenkins, 2015, Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation, Clin Lung Cancer, 16, e101, 10.1016/j.cllc.2015.01.009

Tong, 2016, MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis, Clin Cancer Res, 22, 3048, 10.1158/1078-0432.CCR-15-2061

Wu, 2014, Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: a single-arm phase lb/ll study, Am J Clin Oncol, 32, 8017, 10.1200/jco.2014.32.15_suppl.8017